Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- GSK, DSP Launch Paxil CR Tablets
June 25, 2012
- Nexium Approved for Prevention of GU and DU in Patients Receiving Low-Dose Aspirin: Daiichi Sankyo, AZ
June 25, 2012
- Lyrica Approved for Pain Associated with Fibromyalgia: Pfizer Japan
June 25, 2012
- Two Generic Drug Makers Offer Different Views on Impact of Generic Name-based Prescriptions
June 22, 2012
- Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
June 22, 2012
- Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
June 21, 2012
- Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
June 21, 2012
- Teijin Pharma to Build New Laboratory to Support Increased Feburic Production and New Drug Development
June 21, 2012
- IBL, Trans Genic to Create Joint Venture for Diagnostic Agent Development and Clinical Tests
June 21, 2012
- Daiichi Sankyo to Market Ranbaxy Products in Venezuela
June 21, 2012
- Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review
June 20, 2012
- RDKK Aims at Sales of 55.5 Billion Yen in 2014 Driven by Personalized Medicine: President Ogasawara
June 20, 2012
- Concrete Price Negotiations to Get Underway by August or September: President Choufuku of Mediceo
June 19, 2012
- Nichi-Iko, Mitani Sangyo to Build New Plant in Toyama for APIs
June 19, 2012
- “Sales, Shares Will Follow” Tohoku ALC Opening: Mediceo President Choufuku
June 19, 2012
- DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
June 19, 2012
- Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
June 19, 2012
- Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
June 19, 2012
- [Data] Sales of Takeda’s Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Otsuka HD's Mainstay Products in FY2011
June 19, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…